Pavan Koti* and Tawil Bill

Department of Biotechnology, California State University Channel Islands, One University Drive, Camarillo, CA 93010, USA

*Corresponding Author: Pavan Koti, Department of Biotechnology, California State University Channel Islands, One University Drive, Camarillo, CA 93010, USA.

Received: January 27, 2025; Published: March 10, 2025

Abstract

Papillary thyroid cancer (PTC) is the most common type of thyroid malignancy, characterized by its relatively benign behavior and high survival rates. Despite these positive outcomes, there has been a notable increase in the global incidence of PTC, primarily due to advancements in diagnostic technologies and an enhanced understanding of the disease's genetic underpinnings. This review paper explores the significant strides made in the diagnosis and treatment of PTC, with a strong emphasis on the latest technological and scientific developments. Enhanced genetic profiling has proven instrumental, particularly the identification of mutations such as BRAF V600E and RET, which have crucial implications for targeted therapy and patient management. Moreover, the emerging role of microRNAs in PTC pathogenesis provides new insights into non-invasive diagnostic techniques and innovative treatment approaches. This review also discusses the application of cutting-edge technologies like CRISPR/Cas9 for precise gene editing and artificial intelligence to improve prognostic models, which are poised to significantly refine therapeutic strategies. Challenges such as resistance to traditional therapies like radioactive iodine are addressed, underscoring the critical need for ongoing research into novel biomarkers and therapeutic targets. Collectively, the advancements highlighted in this review illustrate a shift towards more personalized medicine in the management of PTC, aiming to improve patient outcomes and quality of life through tailored treatment approaches.

 Keywords: Papillary Thyroid Cancer (PTC); Genetic Profiling; Molecular Diagnostics; MicroRNAs (miRNAs); Targeted Therapy; Radioactive Iodine (RAI) Therapy; CRISPR/Cas9; Machine Learning; Immunotherapy; Liquid Biopsy

References

1. Li Y., et al. “The Incidence Trend of Papillary Thyroid Carcinoma in the United States During 2003-2017. Cancer Control”. Journal of the Moffitt Cancer Center 29 (2022): 10732748221135447.
2. Minnella A., et al. “Targeting ferroptosis with the lipoxygenase inhibitor PTC-041 as a therapeutic strategy for the treatment of Parkinson’s disease”. PLoS ONE 9 (2024): e0309893.
3. Li Y., et al. “Risk stratification of papillary thyroid cancers using multidimensional machine learning”. International Journal of Surgery1 (2024): 372.
4. Papaleontiou M., et al. “Thyrotropin Suppression for Papillary Thyroid Cancer: A Physician Survey Study”. Thyroid (2021).
5. Jin X., et al. “Cancer-associated fibroblast-derived periostin promotes papillary thyroid tumor growth through integrin-FAK-STAT3 signaling. Theranostics 14 (7 (2024): 3014-3028.
6. Faizullabhoy M and Wani G. “Thyroid Cancer Diagnostics Market Size - By Product (Instruments, Kits and Consumables Type (Papillary Carcinoma, Follicular Carcinoma Technique (Blood Test, Imaging, Biopsy End-use (Hospitals, Cancer Diagnostic Centers) & Forecast, 2024 - 2032”. Global Market Insights Inc (1970).
7. “Thyroid Cancer Market Size, Trends and Forecast”. Delveinsight.com (2022).
8. Aschebrook-Kilfoy B., et al. “The Clinical and Economic Burden of a Sustained Increase in Thyroid Cancer Incidence”. Cancer Epidemiology and Prevention Biomarkers 7 (2013): 1252-1259.
9. Van Den Heede K., et al. “Differentiated Thyroid Cancer: A Health Economic Review”. Cancers 9 (2021): 2253.
10. Market Data Forecast. “Thyroid Cancer Market Size, Analysis & Growth Report, 2032”. Market Data Forecast (2024).
11. Chang L., et al. “An integrated nomogram combining deep learning, clinical characteristics and ultrasound features for predicting central lymph node metastasis in papillary thyroid cancer: A multicenter study”. Frontiers in Endocrinology 14 (2023).
12. Ha E J., et al. “2021 Korean Thyroid Imaging Reporting and Data System and Imaging-Based Management of Thyroid Nodules: Korean Society of Thyroid Radiology Consensus Statement and Recommendations”. Korean Journal of Radiology 12 (2021): 2094.
13. Dominika Januś., et al. “Ultrasound, laboratory and histopathological insights in diagnosing papillary thyroid carcinoma in a paediatric population: a single centre follow-up study between 2000-2022”. Frontiers in Endocrinology 14 (2023).
14. Lu G and Chen L. “Cervical lymph node metastases in papillary thyroid cancer.” Medicine9 (2022): e28909-e28909.
15. Tang Q., et al. “Unenhanced magnetic resonance imaging of papillary thyroid carcinoma with emphasis on diffusion kurtosis imaging”. Quantitative Imaging in Medicine and Surgery 4 (2021): 2697-2707.
16. Sylwia Szpak-Ulczok., et al. “Differences in Gene Expression Profile of Primary Tumors in Metastatic and Non-Metastatic Papillary Thyroid Carcinoma—Do They Exist?” International Journal of Molecular Sciences13 (2020): 4629-4629.
17. Papaioannou M., et al. “MicroRNAs in Papillary Thyroid Cancer: What Is New in Diagnosis and Treatment”. Frontiers in Oncology 11 (2022).
18. Tao Y B., et al. “BRAF V600E Status Sharply Differentiates Lymph Node Metastasis-associated Mortality Risk in Papillary Thyroid”. Cancer11 (2021): 3228-3238.
19. Jensen K., et al. “Detection of BRAFV600E in Liquid Biopsy from Patients with Papillary Thyroid Cancer Is Associated with Tumor Aggressiveness and Response to Therapy”. Journal of Clinical Medicine8 (2020): 2481-2481.
20. Wang W., et al. “CTC, ctDNA, and Exosome in Thyroid Cancers: A Review”. International Journal of Molecular Sciences, 24 (18 (2023): 13767.
21. Toro-Tobon D., et al. “Artificial Intelligence in Thyroidology: A Narrative Review of the Current Applications, Associated Challenges, and Future Directions”. Thyroid8 (2023): 903-917.
22. Zheng Y., et al. “Diagnostic value of an interpretable machine learning model based on clinical ultrasound features for follicular thyroid carcinoma”. Quantitative Imaging in Medicine and Surgery9 (2024): 6311-6324.
23. Ludwig M., et al. “The Use of Artificial Intelligence in the Diagnosis and Classification of Thyroid Nodules: An Update”. Cancers3 (2023): 708.
24. Luvhengo T E., et al. “Holomics and Artificial Intelligence-Driven Precision Oncology for Medullary Thyroid Carcinoma: Addressing Challenges of a Rare and Aggressive Disease”. Cancers 20 (2024): 3469.
25. Papaioannou M., et al. “MicroRNAs in papillary thyroid cancer: What is new in diagnosis and treatment”. Frontiers in Oncology 11 (2022): 755097.
26. Guo H., et al. “Radioactive iodine therapy strategies for distinct types of differentiated thyroid cancer: A propensity score-matched analysis”. Frontiers in Endocrinology 14 (2023): 1158581.
27. Oh J M and Ahn BC. “Molecular mechanisms of radioactive iodine refractoriness in differentiated thyroid cancer: Impaired sodium iodide symporter (NIS) expression owing to altered signaling pathway activity and intracellular localization of NIS”. Theranostics 13 (2021): 6251-6277.
28. Minnella A., et al. “Targeting ferroptosis with the lipoxygenase inhibitor PTC-041 as a therapeutic strategy for the treatment of Parkinson’s disease”. PLoS ONE9 (2024): e0309893.
29. Chen D., et al. “Papillary thyroid cancer organoids harboring BRAFV600E mutation reveal potentially beneficial effects of BRAF inhibitor-based combination therapies”. Journal of Translational Medicine1 (2023).
30. Aljammal J., et al. “Radiofrequency Ablation: A Novel Treatment Option for Neck Recurrence in Medullary Thyroid Carcinoma”. Journal of the Endocrine Society 5 (2021): A898-A899.
31. “Understanding Radioactive Iodine Resistance in Thyroid Cancer: Overcoming Treatment Challenges - Qualisure Diagnostics”. Qualisure Diagnostics (2023).
32. Liu Y., et al. “Radioiodine therapy in advanced differentiated thyroid cancer: Resistance and overcoming strategy”. Drug Resistance Updates 68 (2023): 100939.
33. Khatami F., et al. “Personalized treatment options for thyroid cancer: current perspectives”. Pharmacogenomics and Personalized Medicine 12 (2019): 235-245.
34. Sakhr Abdulsalam Alshwayyat., et al. “Precision medicine for papillary thyroid carcinoma (PTC) variants: A machine learning approach to prognosis and treatment guidance”. Journal of Clinical Oncology16 (2024): e18072-e18072.
35. Sava J. “Personalized Approaches and Emerging Therapies Transform Thyroid Cancer Treatment”. Targeted Oncology (2024).
36. Fuziwara C S., et al. “Gene editing with CRISPR/Cas methodology and thyroid cancer: Where are we?” Cancers 3 (2022): 844.
37. Song B., et al. “Global research landscape and trends of papillary thyroid cancer therapy: A bibliometric analysis”. Frontiers in Endocrinology 14 (2023): 1252389.v
38. Al-Jundi M., et al. “Novel Targeted Therapies for Metastatic Thyroid Cancer—A Comprehensive Review”. Cancers8 (2020): 2104.
39. Huang LC., et al. “CRISPR/Cas9 Genome Editing of Epidermal Growth Factor Receptor Sufficiently Abolished Oncogenicity in Anaplastic Thyroid Cancer”. Disease Markers (2018): 1-14.
40. “Papillary Thyroid Cancer”. Columbia University Department of Surgery.
41. “Thyroid Cancer Risk Factors”.
42. “Risk Factors and Symptoms of Thyroid Cancer”. Rogel Cancer Center (2018).
43. Bogović Crnčić T. “Risk Factors for Thyroid Cancer: What Do We Know So Far?” Acta Clinica Croatica (2020).

Citation

Citation: Pavan Koti and Tawil Bill. “Current Trends and Advances in Papillary Thyroid Cancer: A Focus on Personalized Medicine and Technological Advancements”.Acta Scientific Medical Sciences 9.4 (2025): 32-44.

Copyright

Copyright: © 2025 Pavan Koti and Tawil Bill. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.